Blackstone bets $750M on Moderna’s flu program as approval comes into view
Blackstone Life Sciences is making a $750 million bet on Moderna’s influenza vaccine program as part of the investment platform’s push to “support innovative mRNA technology.” | Blackstone Life Sciences is making a $750 million bet on Moderna’s influenza vaccine program as part of the investment platform’s push to “support innovative mRNA technology.”